Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
NBIX POWR Grades
- NBIX scores best on the Value dimension, with a Value rank ahead of 92.61% of US stocks.
- The strongest trend for NBIX is in Value, which has been heading up over the past 31 weeks.
- NBIX ranks lowest in Momentum; there it ranks in the 5th percentile.
NBIX Stock Summary
- Neurocrine Biosciences Inc's market capitalization of $9,277,798,097 is ahead of 80.41% of US-listed equities.
- The price/operating cash flow metric for Neurocrine Biosciences Inc is higher than 85.39% of stocks in our set with a positive cash flow.
- The volatility of Neurocrine Biosciences Inc's share price is greater than that of merely 12.65% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Neurocrine Biosciences Inc, a group of peers worth examining would be CRUS, UTHR, GPX, DLB, and WWD.
- Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.
NBIX Valuation Summary
- In comparison to the median Healthcare stock, NBIX's EV/EBIT ratio is 165.5% higher, now standing at 75.8.
- Over the past 243 months, NBIX's price/sales ratio has gone down 55.6.
- Over the past 243 months, NBIX's price/earnings ratio has gone up 52.5.
Below are key valuation metrics over time for NBIX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| NBIX | 2019-12-20 | 15.0 | 17.6 | 479.5 | 178.7 |
| NBIX | 2013-11-06 | 24.4 | 4.6 | -22.7 | -21.2 |
| NBIX | 2011-11-11 | 4.8 | 6.6 | 9.8 | 8.7 |
| NBIX | 2007-11-08 | 38.2 | 1.6 | -4.1 | -4.2 |
| NBIX | 2003-08-06 | 30.3 | 7.2 | -16.7 | -16.2 |
| NBIX | 2002-08-07 | 26.5 | 3.8 | -27.4 | -26.6 |
NBIX Growth Metrics
- Its 4 year net cashflow from operations growth rate is now at 717.53%.
- Its 5 year price growth rate is now at 107.08%.
- Its 2 year price growth rate is now at 27.63%.
The table below shows NBIX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 1,045.4 | 277.6 | 402 |
| 2020-12-31 | 1,045.9 | 228.5 | 407.3 |
| 2020-09-30 | 1,042.01 | 242.153 | 93.4 |
| 2020-06-30 | 1,005.604 | 357.479 | 204.789 |
| 2020-03-31 | 886.784 | 302.745 | 176.527 |
| 2019-12-31 | 788.087 | 152.054 | 37.012 |
NBIX Price Target
For more insight on analysts targets of NBIX, see our NBIX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $122.35 | Average Broker Recommendation | 1.46 (Moderate Buy) |
NBIX Stock Price Chart Interactive Chart >
NBIX Price/Volume Stats
| Current price | $94.10 | 52-week high | $126.71 |
| Prev. close | $95.77 | 52-week low | $86.02 |
| Day low | $93.12 | Volume | 778,854 |
| Day high | $95.47 | Avg. volume | 961,979 |
| 50-day MA | $97.04 | Dividend yield | N/A |
| 200-day MA | $98.82 | Market Cap | 8.90B |
Neurocrine Biosciences, Inc. (NBIX) Company Bio
Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.
Latest NBIX News From Around the Web
Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.
Immunotoxins Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Biotest, Celldex Therapeutics, Amgen, Genmab, AREVA Med, Bayer HealthCare, Neurocrine Biosciences,This report studies the Immunotoxins Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Immunotoxins market segmented by company, region, type and applications [] |
United States Parkinson''s Disease Market Insights, Epidemiology and Outlook to 2030 | Addex Pharma, AbbVie, Prevail Therapeutics, Denali Therapeutics, Neurocrine Biosciences, and MoreDUBLIN, July 23, 2021 /PRNewswire/ -- The |
Hedge Funds Never Been Less Bullish On Neurocrine Biosciences, Inc. (NBIX)We at Insider Monkey have gone over 866 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds’ and investors’ portfolio positions as of March 31st. In this article, we look at what those funds think of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) based on that […] |
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial ResultsNeurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time). |
Essential Tremor Treatment Market Growth 2021-2026: Merz Pharma GmbH & Co KgaA , Neurocrine Biosciences Inc , Sage Therapeutics IncEssential Tremor Treatment Market analysis report is sure to help boost sales and improve return on investment (ROI). The research and analysis carried out in this Essential Tremor Treatment Market report assist clients to forecast investment in an emerging market, expansion of market share or success of a new product with the help of global […] |
NBIX Price Returns
| 1-mo | -6.17% |
| 3-mo | -3.68% |
| 6-mo | -15.93% |
| 1-year | -25.32% |
| 3-year | -12.24% |
| 5-year | 87.64% |
| YTD | -1.83% |
| 2020 | -10.83% |
| 2019 | 50.53% |
| 2018 | -7.96% |
| 2017 | 100.49% |
| 2016 | -31.59% |
Continue Researching NBIX
Want to do more research on Neurocrine Biosciences Inc's stock and its price? Try the links below:Neurocrine Biosciences Inc (NBIX) Stock Price | Nasdaq
Neurocrine Biosciences Inc (NBIX) Stock Quote, History and News - Yahoo Finance
Neurocrine Biosciences Inc (NBIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...